Lauren:
Oh my goodness. Where to start.
I don't believe in prophylactic Rituxan. Here's why. I think my last Rituxan was in 2004. I had one treatment, then got my second serum sickness episode. It was determined then that I should never have Rituxan again, but anyway, counts went up to 150 and have been normal since (that's nearly 9 years of remission). If I'd never had serum sickness, and if I'd had Rituxan prophylactically, say even two treatments a year, I'd have been given 18 Rituxan infusions for absolutely no reason since we'd never have known that my counts would have stayed up without any treatment at all.
Rituxan is a toxic drug that can cause problems over time. It can lower immunity, especially for someone with Lupus. It can raise the risk of cancer (already an elevated risk for someone with Lupus). Most of the time with ITP, there is no real harm in waiting until you need to be treated. I've never seen any real reason to prevent a drop and keep counts in a normal range if a person does respond to treatments. Since ITP can be chronic, the less drugs over time, the better.
Then there is the possibility that you did have serum sickness. It's a shame that you were not properly diagnosed, because you need to take that seriously. Your doctors should be taking a good look at that too. It's not something that should be blown off. After my second serum sickness, I was never the same. It stirred up inflammation that I have never been able to get rid of. If I hadn't been misdiagnosed the first time, I'd be a lot better off right now. Serum sickness reactions can get worse and can cause death.
Also, I've read a lot of studies about Lupus and Rituxan and the reviews are not all that great. It can work for some and do nothing for others.
There was more disappointing news for rituximab (Rituxan) and its potential role as a lupus therapy, however. Rituximab is a monoclonal antibody that depletes CD-20 B cells. Joan T. Merrill, MD, professor of medicine at the University of Oklahoma Health Sciences Center in Oklahoma City, presented data from two analyses of an ongoing trial evaluating rituximab in people with moderate-to severe lupus.
In the phase II/III EXPLORER trial, participants were taking immunosuppressants and steroids. They received four infusions over six months of either a placebo or rituximab, during which the steroids were gradually stopped. After 78 weeks, the rate of serious and minor adverse events, including infection and infusion reactions, were similar between the two groups, although there was a higher incidence of viral herpes, neutropenia and serum sickness in the rituximab group.
A study evaluating the subset of participants who showed a response to either placebo or rituximab found that severe and moderate flare rates were similar in both groups during the year they were followed. However, the average flare rate in the rituximab group was significantly lower than in the placebo group, suggesting that rituximab may increase the time to flare compared with placebo.
The results of the EXPLORER trial troubled clinicians, many of whom use rituximab for patients with lupus even though the drug has not been approved for that use yet. When asked how the results should be interpreted, Dr. Merrill replied: "while there is no evidence that rituximab works, I'm dissatisfied with the evidence that it doesn't."
And, in fact, other studies of the drug presented during the meeting show differing results.
A study in 35 African-American and Hispanic patients who received four weekly infusions and were followed for two years showed a significant drop in disease activity throughout the study in all participants, even those with lupus nephritis.
A study in 86 peopled with lupus treated with rituximab with or without other lupus treatments for an average of 15 months found that an estimated 73% of treated patients showed improvement. Overall, 10 people had severe infections and one died from an infection.
What this means for people with lupus? It is quite likely that rituximab works in certain populations of people with lupus. The disappointing results from the large, manufacturer-sponsored clinical trials may be related to the way the trials were designed. The decision to use or not use rituximab is one you should make in conjunction with your doctor. www.lupusresearch.org/research/acr/latest_advances.html This is all just my opinion. You have to do what you think is best for you. However, having two autoimmune disorders also, I can tell you that the number of drugs you use will increase in time and that can accumulate to a lot of meds in years to come. I have tried so many and all have come with a price. I've come to the conclusion, if it ain't broke, don't try to fix it.